| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/01/2004 | US20040127481 Administering a therapeutic amount of a lidocaine, verapamil, diltiazem, isometheptene, or lisuride condensation aerosol |
| 07/01/2004 | US20040127474 Contacting the cell with a ptc agonist in a sufficient amount to inhibit the altered growth state, wherein the ptc agonist is a organic molecule having a molecular weight less than about 750 amu for inhibiting an altered growth state of a cell |
| 07/01/2004 | US20040127468 phosphatidic acid decreases apoptosis induced by the sudden withdrawal of NGF and serum (trophic withdrawal), rotenone, and glutamate |
| 07/01/2004 | US20040127464 potent, selective and safe inhibitors of the Ca2+-activated potassium channel |
| 07/01/2004 | US20040127462 Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae |
| 07/01/2004 | US20040127454 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases |
| 07/01/2004 | US20040127438 polypeptide (or its encoding nucleic acid molecule from Mycobacterium tuberculosis or related prokaryotes in the treatment of cancer, allergic disorders or conditions of immunoactivation, particularly asthma |
| 07/01/2004 | US20040127431 for example, benign prostate hyperplasia (BPH), fibroplastic dysplasia of the breast, fibroplastic growth in the uterus or fibroplastic growth in the cervix |
| 07/01/2004 | US20040127429 glycolipid ligand for natural killer T (NKT) cells; synthetic analogs of alpha -C-galactosylceramides |
| 07/01/2004 | US20040127424 Inhibitors of cruzipain and other cysteine proteases |
| 07/01/2004 | US20040127408 based on the complementarity-determining region (CDR) of a human monoclonal anti-DNA antibody |
| 07/01/2004 | US20040127399 complex consisting of a divalent metal cation associated with and capable of co-precipitating with such a peptide for enhancing the expression of insulin from mammalian pancreatic B-type islet cells |
| 07/01/2004 | US20040126870 Ncc2705-the genome of a bifodobacterium |
| 07/01/2004 | US20040126859 Mutant forms of Fas ligand and uses thereof |
| 07/01/2004 | US20040126810 Peptide substrate identified by type bont/b botulinus toxin and use thereof for assaying and/or detecting said toxin or corresponding inhibitors |
| 07/01/2004 | US20040126759 Molecules for disease detection and treatment |
| 07/01/2004 | US20040126447 Extract of Dioscorea sp. and the medical uses thereof |
| 07/01/2004 | US20040126423 Pharmaceutical formulation |
| 07/01/2004 | US20040126420 phosphatidylcholine, sphingomyelin, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl inositol, and cholesterol; for removal of extra-/intra- vascular fibrin clots/adhesions; for use during surgery; for treatment of otitis |
| 07/01/2004 | US20040126367 Oxidation resistance; storage at low temperature; overcoated with liposomes from soybean lecithin |
| 07/01/2004 | US20040126364 Antiinflammatory agents; genetic engineered interleukins; oral diseases |
| 07/01/2004 | US20040126359 Modulate lymphocyte activation; cell proliferation; apoptosis; signal transduction |
| 07/01/2004 | US20040126356 Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| 07/01/2004 | US20040126329 Delivery of analgesics through an inhalation route |
| 07/01/2004 | US20040126328 Arerosol; heating drug, vaporization, cooling |
| 07/01/2004 | US20040126327 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 07/01/2004 | US20040126326 Delivery of antidepressants through an inhalation route |
| 07/01/2004 | DE10259244A1 N-(Indolethyl-)cycloamin-Verbindungen N- (Indolethyl-) cyclo amine compounds |
| 07/01/2004 | CA2510683A1 Carbazole derivatives and their use as npy-5 antagonists |
| 07/01/2004 | CA2510169A1 N-(indolethyl-)cycloamine compounds |
| 07/01/2004 | CA2509615A1 Gabapentin analogues for fibromyalgia and other related disorders |
| 07/01/2004 | CA2509356A1 Glucose and/or fructose transporter naglt1 and its gene |
| 07/01/2004 | CA2508825A1 Vaccine for fish cold-water disease |
| 07/01/2004 | CA2508297A1 Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
| 07/01/2004 | CA2505788A1 Pregabalin derivatives for the treatment of fibromyalgia and other disorders |
| 06/30/2004 | EP1433792A2 Human receptor proteins, related reagents and methods |
| 06/30/2004 | EP1433781A1 Pyrrolidine carboxylic acid derivatives |
| 06/30/2004 | EP1433779A1 Use of nitriles as inhibitors of non-proteolytic enzymes |
| 06/30/2004 | EP1433778A1 Use of nitriles as rotamase inhibitors |
| 06/30/2004 | EP1433776A1 Carba-sugar amine derivatives and treatments for disorder of glycolipid metabolism containing the same as the active ingredient |
| 06/30/2004 | EP1433482A1 Aqueous preparation containing a shark-derived chondroitin iron sulfate colloid |
| 06/30/2004 | EP1433480A1 Medicine containing pyrimidine derivative |
| 06/30/2004 | EP1433479A1 Appetite-stimulating agents and remedies for anorexia |
| 06/30/2004 | EP1432991A1 Identification and isolation of somatic stem cells and uses thereof |
| 06/30/2004 | EP1432801A2 Receptors and membrane-associated proteins |
| 06/30/2004 | EP1432738A1 Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them |
| 06/30/2004 | EP1432734A1 Cytokine receptor |
| 06/30/2004 | EP1432733A2 Gene regulatory peptides |
| 06/30/2004 | EP1432728A2 Methods and compositions for treating inflammatory disorders |
| 06/30/2004 | EP1432724A1 Rna interference mediated inhibition of map kinase genes |
| 06/30/2004 | EP1432718A1 Chemical compounds |
| 06/30/2004 | EP1432715A2 Pyrimidine derivatives |
| 06/30/2004 | EP1432714A2 Chemical compounds |
| 06/30/2004 | EP1432711A1 1,6-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432710A1 1, 8-naphthyridine derivatives as antidiabetics |
| 06/30/2004 | EP1432706A2 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors |
| 06/30/2004 | EP1432702A1 Nitrogen-containing heterocyclic compounds and their use as raf inhibitors |
| 06/30/2004 | EP1432701A1 Heterocyclic compounds for use in the treatment of disorders of the urinary tract |
| 06/30/2004 | EP1432699A1 Pyridylfurans and pyrroles as raf kinase inhibitors |
| 06/30/2004 | EP1432698A2 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors |
| 06/30/2004 | EP1432697A1 Pyridylfurans and pyrroles as raf kinase inhibitors |
| 06/30/2004 | EP1432693A2 Mch receptor antagonists |
| 06/30/2004 | EP1432690A2 Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence |
| 06/30/2004 | EP1432687A2 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 06/30/2004 | EP1432686A1 Tetrahydroisochinolines, their production and the use thereof as analgesics |
| 06/30/2004 | EP1432684A2 Pyridinic sulfonamide derivatives, method of production and use thereof |
| 06/30/2004 | EP1432679A1 Preparation and use of pyrrole derivatives for treating obesity |
| 06/30/2004 | EP1432452A2 Inhibition of stat-1 |
| 06/30/2004 | EP1432448A2 Novel molecules of the hkid-1-related protein family and uses thereof |
| 06/30/2004 | EP1432447A2 Combined compositions and methods for tumor vasculature coagulation and treatment |
| 06/30/2004 | EP1432444A2 Anti-a-beta antibodies |
| 06/30/2004 | EP1432440A2 Adjuvants for nucleic acid vaccines |
| 06/30/2004 | EP1432438A2 Use of rank antagonists to treat cancer |
| 06/30/2004 | EP1432436A2 Nutrient therapy for immuno-compromised patients |
| 06/30/2004 | EP1432435A1 Enamel matrix protein compositions for modulating immune response |
| 06/30/2004 | EP1432433A2 Antagonists |
| 06/30/2004 | EP1432431A2 Methods and compositions for modulating interleukin-21 receptor activity |
| 06/30/2004 | EP1432425A1 A method of reducing the "in vivo" cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl) |
| 06/30/2004 | EP1432424A1 Heterocyclic substituted 2- (4-phenoxy) pyridine derivatives and related compounds as sodium channel blockers for the treatment of neuronal damage and neurodegenerative conditions |
| 06/30/2004 | EP1432423A2 Pharmaceutical combinations of pde-v inhibitors and other agents |
| 06/30/2004 | EP1432421A1 Quinoline derivatives as neuropeptide y antagonists |
| 06/30/2004 | EP1432420A2 Benzimidazolidinone derivatives as muscarinic agents |
| 06/30/2004 | EP1432419A1 Aryl substituted pyridinecarboxamides and their use as sodium channel blockers |
| 06/30/2004 | EP1432418A1 Treatment of hepatitis b virus infection with human monoclonal antibodies |
| 06/30/2004 | EP1432417A2 Substituted benzimidazole compounds and their use for the treatment of cancer |
| 06/30/2004 | EP1432416A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 06/30/2004 | EP1432407A1 Lisinopril compositions having large-particle dcpd |
| 06/30/2004 | EP1432403A2 Liposome loading with metal ions |
| 06/30/2004 | EP1432399A1 Enhancing epidermal barrier development in skin |
| 06/30/2004 | EP1326851B1 Substituted dipeptides as growth hormone secretagogues |
| 06/30/2004 | EP1315730B1 1-(alkyl), 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridinyl-imidazo(1,2-a)pyrimidin-5(1h)-one derivatives |
| 06/30/2004 | EP1237543A4 Effervescent histamine h2 antagonist composition |
| 06/30/2004 | EP1237524A4 Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
| 06/30/2004 | EP1214313B1 Heteroaryloxy propanolamines, preparation method and pharmaceutical compositions containing same |
| 06/30/2004 | EP1173413B1 Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors |
| 06/30/2004 | EP1149072B1 Sulfonamide hydroxamates |
| 06/30/2004 | EP1113802B1 Antiviral combinations of lamivudine and adefovir |
| 06/30/2004 | EP1070056B1 Phthalazinone pde iii/iv inhibitors |
| 06/30/2004 | EP1070049B1 Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors |
| 06/30/2004 | EP1045693B1 Aminophenoxyacetic acid derivatives as neuroprotectants |